CLSDQ — Clearside Biomedical, Inc.

OTC · Health Care · Pharmaceuticals · CIK 1539029 ·
Last close
$0.31
Market Cap
$1.65M
52W High
$0.85
52W Low
$0.04
ADV30
15,443
Next earnings
2026-05-06
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 201,000 201,000 -7,040,000 -5,972,000 11,641,000 6,801,000 65,591,000
Jun 2025 492,000 492,000 -3,568,000 -4,495,000 15,332,000 9,376,000 64,066,000
Mar 2025 2,330,000 2,082,000 -5,205,000 -8,223,000 19,668,000 13,628,000 65,578,000
Dec 2024 306,000 157,000 -7,149,000 -7,306,000 25,126,000 20,020,000 63,981,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-21,293,000
Investing CF
$9,298,000
Financing CF
$4,908,000
CapEx
$-506,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-5.19
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-373,965,000
Inventory
Receivables
$266,000
ST Investments
$9,703,000
EBIT TTM
$-14,697,000
Pretax Income TTM
$-25,281,000
Interest Exp TTM
$10,584,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,329,000
EBITDA
$-22,630,000
Free Cash Flow
$-20,525,250
Enterprise Value
$56,461,228
Total Cash
$6,801,000
Total Debt
$61,613,000
Shares Out
5,233,981
Trailing EPS
$-5.11
Book Value
$-10.31
ROE
ROA
-70.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 1,664,000 -28,882,000 -34,352,000 25,126,000 63,981,000 -24,698,000
Dec 2023 8,226,000 -24,844,000 -32,485,000 34,018,000 49,930,000 -18,135,000
Dec 2022 1,327,000 -30,277,000 -32,947,000 51,303,000 40,696,000 -13,365,000
Dec 2021 29,575,000 -627,000 376,000 42,903,000 4,928,000 -10,733,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-4.80

Peers — same industry

TickerNameMarket CapLastDaily %
UPC Universe Pharmaceuticals INC $1.65M $2.61
PCYN PROCYON CORP $1.64M $0.20
JAGX Jaguar Health, Inc. $1.60M $3.11
AXIM AXIM BIOTECHNOLOGIES, INC. $1.80M $0.01
ZVSA ZyVersa Therapeutics, Inc. $1.46M $0.18

News headlines (Yahoo Finance, 1h cache)

New Strong Sell Stocks for January 21st
2026-01-21 09:51 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.